Compared with sustained PI monotherapy, a combination therapy strategy using PIs and HDAC inhibitors or an increased dosage intermittent therapy can be more effective in treating MM by preventing the emergence of tolerant cancer cells. The gene discussed is HDAC9; the disease is cancer.